Profund Advisors LLC Bridge Bio Pharma, Inc. Transaction History

Profund Advisors LLC

$2.59 Billion
Q3 2024

A detailed history of Profund Advisors LLC transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Profund Advisors LLC holds 48,966 shares of BBIO stock, worth $1.36 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

48,966

Previous 51,029 4.04%

Holding current value

$1.36 Million

Previous $1.29 Million 3.56%

% of portfolio

0.05%

Previous 0.05%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$23.91 - $31.3 $49,326 - $64,571	-2,063 Reduced 4.04%	48,966 $1.25 Million
Q2 2024 Aug 13, 2024	BUY	$23.0 - $31.04 $12,765 - $17,227	555 Added 1.1%	51,029 $1.29 Million
Q1 2024 May 08, 2024	BUY	$27.35 - $40.45 $112,873 - $166,937	4,127 Added 8.9%	50,474 $1.56 Million
Q4 2023 Feb 14, 2024	SELL	$24.02 - $43.89 $180,678 - $330,140	-7,522 Reduced 13.96%	46,347 $1.87 Million
Q3 2023 Nov 13, 2023	SELL	$16.89 - $35.01 $685,666 - $1.42 Million	-40,596 Reduced 42.97%	53,869 $1.42 Million
Q2 2023 Aug 10, 2023	BUY	$13.29 - $18.01 $580,666 - $786,892	43,692 Added 86.05%	94,465 $1.62 Million
Q1 2023 May 11, 2023	BUY	$7.17 - $18.55 $364,042 - $941,839	50,773 New	50,773 $841,000
Q2 2022 Aug 01, 2022	SELL	$5.21 - $12.14 $10,284 - $23,964	-1,974 Reduced 11.95%	14,549 $132,000
Q1 2022 May 10, 2022	SELL	$7.34 - $17.16 $13,498 - $31,557	-1,839 Reduced 10.02%	16,523 $168,000
Q4 2021 Feb 08, 2022	SELL	$11.38 - $53.41 $28,643 - $134,432	-2,517 Reduced 12.06%	18,362 $306,000
Q3 2021 Nov 12, 2021	BUY	$46.87 - $64.24 $978,598 - $1.34 Million	20,879 New	20,879 $979,000

Others Institutions Holding BBIO

# of Institutions

290

Shares Held

170M

Call Options Held

10.4M

Put Options Held

2.37M

View Full List

About BridgeBio Pharma, Inc.

Ticker BBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 148,246,000
Market Cap $4.12B
Description
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...

More about BBIO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.

Account

Profund Advisors LLC Bridge Bio Pharma, Inc. Transaction History